U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Bladder Carcinoma

MedGen UID:
1712361
•Concept ID:
C5238243
•
Neoplastic Process

Definition

Bladder carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Bladder Carcinoma

Professional guidelines

PubMed

Treatment of chemotherapy-refractory metastatic urothelial tumors.
Logothetis C
Urol Clin North Am 1992 Nov;19(4):775-7. PMID: 1441031

Recent clinical studies

Therapy

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators
Ann Oncol 2024 Jan;35(1):107-117. Epub 2023 Oct 21 doi: 10.1016/j.annonc.2023.10.003. PMID: 37871702
Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma.
van der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD; CheckMate 901 Trial Investigators
N Engl J Med 2023 Nov 9;389(19):1778-1789. Epub 2023 Oct 22 doi: 10.1056/NEJMoa2309863. PMID: 37870949
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group
Lancet Oncol 2022 Feb;23(2):248-258. Epub 2022 Jan 11 doi: 10.1016/S1470-2045(21)00660-4. PMID: 35030333
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators
Lancet Oncol 2021 Jul;22(7):931-945. Epub 2021 May 26 doi: 10.1016/S1470-2045(21)00152-2. PMID: 34051178

Prognosis

Acquired semi-squamatization during chemotherapy suggests differentiation as a therapeutic strategy for bladder cancer.
Wang M, Chen X, Tan P, Wang Y, Pan X, Lin T, Jiang Y, Wang B, Xu H, Wang Y, Yang Y, Wang J, Zhao L, Zhang J, Zhong A, Peng Y, Du J, Zhang Q, Zheng J, Chen J, Dai S, Na F, Lu Z, Liu J, Zheng X, Yang L, Zhang P, Han P, Gong Q, Zhong Q, Xiao K, Yang H, Deng H, Zhao Y, Shi H, Man J, Gou M, Zhao C, Dai L, Xue Z, Chen L, Wang Y, Zeng M, Huang C, Wei Q, Wei Y, Liu Y, Chen C
Cancer Cell 2022 Sep 12;40(9):1044-1059.e8. doi: 10.1016/j.ccell.2022.08.010. PMID: 36099882
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group
Lancet Oncol 2022 Feb;23(2):248-258. Epub 2022 Jan 11 doi: 10.1016/S1470-2045(21)00660-4. PMID: 35030333
Immune checkpoint inhibitors for metastatic bladder cancer.
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A
Cancer Treat Rev 2018 Mar;64:11-20. Epub 2018 Jan 31 doi: 10.1016/j.ctrv.2017.12.007. PMID: 29407369
Update on the Diagnosis and Treatment of Cholangiocarcinoma.
Doherty B, Nambudiri VE, Palmer WC
Curr Gastroenterol Rep 2017 Jan;19(1):2. doi: 10.1007/s11894-017-0542-4. PMID: 28110453
Bile duct malignancies.
Tucek S, Tomasek J, Halámkova J, Kiss I, Andrasina T, Hemmelová B, Adámková-Krákorová D, Vyzula R
Klin Onkol 2010;23(4):231-41. PMID: 20806821

Clinical prediction guides

Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
Miyake M, Nishimura N, Oda Y, Miyamoto T, Ohmori C, Takamatsu N, Itami Y, Tachibana A, Matsumoto Y, Kiba K, Tomioka A, Yamamoto H, Okajima E, Masaomi K, Sakamoto K, Tomizawa M, Shimizu T, Ohnishi K, Hori S, Morizawa Y, Gotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K; Nara Urological Research and Treatment Group
Jpn J Clin Oncol 2024 Mar 9;54(3):329-338. doi: 10.1093/jjco/hyad170. PMID: 38061911
Safety and effectiveness of pembrolizumab monotherapy in Japanese patients with unresectable urothelial carcinoma: a nation-wide post-marketing surveillance.
Nishiyama H, Tanaka Y, Hamada M, Ozaki M, Minegishi T, Ito Y, Maekawa S, Yamamoto N
BMC Cancer 2023 Jun 20;23(1):565. doi: 10.1186/s12885-023-10930-2. PMID: 37340317Free PMC Article
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY, Fradet Y, Oudard S, Vulsteke C, Morales Barrera R, Fléchon A, Gunduz S, Loriot Y, Rodriguez-Vida A, Mamtani R, Yu EY, Nam K, Imai K, Homet Moreno B, Alva A; KEYNOTE-361 Investigators
Lancet Oncol 2021 Jul;22(7):931-945. Epub 2021 May 26 doi: 10.1016/S1470-2045(21)00152-2. PMID: 34051178
Immune checkpoint inhibitors for metastatic bladder cancer.
Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, Battelli N, Ardizzoni A
Cancer Treat Rev 2018 Mar;64:11-20. Epub 2018 Jan 31 doi: 10.1016/j.ctrv.2017.12.007. PMID: 29407369
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Shelley MD, Cleves A, Wilt TJ, Mason MD
BJU Int 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x. PMID: 21718430

Recent systematic reviews

Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
Koufopoulou M, Miranda PAP, Kazmierska P, Deshpande S, Gaitonde P
Cancer Treat Rev 2020 Sep;89:102072. Epub 2020 Jul 22 doi: 10.1016/j.ctrv.2020.102072. PMID: 32769039

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...